# Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC

> **NCT05448781** · PHASE2 · UNKNOWN · sponsor: **Affiliated Cancer Hospital & Institute of Guangzhou Medical University** · enrollment: 38 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Endostatin

## Interventions

- **DRUG:** Endostatin

## Key facts

- **NCT ID:** NCT05448781
- **Lead sponsor:** Affiliated Cancer Hospital & Institute of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-07-20
- **Primary completion:** 2023-07-20
- **Final completion:** 2023-12-20
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2022-07-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05448781

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05448781, "Recombinant Human Angioendostatin /PD-1 Mab Combined With First-line Chemotherapy in the Treatment of Driver Gene Negative Advanced NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05448781. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*